newsfilter
← Latest News
PR Newswire·

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

EWTX
  • Servier will acquire Edgewise Therapeutics' muscular dystrophy business and sevasemten for $1.55 billion in upfront cash and up to $1.1 billion in milestones.
  • The transaction creates an aggregate potential value of $2.65 billion for Edgewise.
  • Proceeds will fully fund the development of EDG-7500 through potential approval.
  • Edgewise will transition to a focused cardiovascular company with a pipeline including EDG-7500, EDG-15400, and EDG-003.
  • Servier will acquire all rights to sevasemten, including intellectual property, regulatory filings, and clinical data.
  • Employees supporting the muscular dystrophy business will receive comparable offers from Servier.
  • Edgewise expects to report 12-week CIRRUS-HCM Part D data for EDG-7500 in Q2 2026.
  • Phase 3 initiation for EDG-7500 is targeted for Q4 2026.
  • Edgewise plans to initiate a Phase 2 trial for EDG-15400 in heart failure with preserved ejection fraction.
  • The transaction is subject to customary closing conditions, including Hart-Scott-Rodino waiting period expiration.
  • Closing is expected in Q3 2026 following unanimous board approvals.
  • Advisors include Centerview Partners LLC as financial advisor to Edgewise.
  • Sevasemten is in late-stage trials for Becker and Duchenne muscular dystrophy with top-line GRAND CANYON data expected in Q4 2026.